Squeeze Report — June 26, 2026
Biotech dominates today's book with a dense cluster of pre-revenue, high-burn names facing binary FDA or data catalysts, but the real tension sits in names like FRMM and GPGI where extreme short interest collides with cheap borrow and dilution overhangs.
Today's top short-squeeze candidates
- #1RZLTRezolute, Inc. Common Stock (N83
The 51.5% 20-day surge pressures shorts, yet abundant, 0.25%-fee borrow and the failed sunRIZE trial give bears cheap ammunition to wait out the upLIFT readout.
SI 21%DTC 11.9$5.03+52% 20dHealthcare - #2ORICOric Pharmaceuticals, Inc. Com80
45% of float sold short · 17.2 days to cover · +10% over 20 days
SI 45%DTC 17.2$9.46+10% 20dHealthcare - #3LQDALiquidia Corporation Common St79
A 79.4 squeeze score hinges entirely on a binary patent ruling, with heavy insider selling and cheap borrow suggesting shorts like their odds.
SI 16%DTC 7.8$76.92+24% 20dHealthcare - #4CADLCandel Therapeutics, Inc. Comm79
30% of float sold short · 7.6 days to cover · +18% over 20 days
SI 30%DTC 7.6$9.47+18% 20dHealthcare - #5AVTXAvalo Therapeutics, Inc. Commo79
59% of float sold short · 4.4 days to cover · +14% over 20 days
SI 59%DTC 4.4$18.00+14% 20dHealthcare - #6GOGrocery Outlet Holding Corp. C79
Insider buying and a 16% rally have already run the stock 22.8% off lows, while negative Q2 comp guidance and near-zero IV cap further squeeze potential.
SI 28%DTC 7.7$9.53+16% 20dConsumer Defensive - #7PTCTPTC Therapeutics, Inc. Common78
A 78.45 squeeze score is driven by technicals, while declining revenue, a $2.33B royalty liability, and convertible maturity overhang anchor the bear case.
SI 15%DTC 11.1$84.51+20% 20dHealthcare - #8ORKAOruka Therapeutics, Inc. Commo78
A 49% surge on M&A speculation pressures a 24.1% short, but 48 insider sales and a $700M offering overhang suggest the smart money is selling the rips.
SI 24%DTC 5.0$86.63+49% 20dHealthcare - #9PARPAR Technology Corp.77
Fifty-four insider buys signal conviction, but a 47% convertible dilution overhang and McDonald's concentration risk explain why 34.2% of the float is short.
SI 34%DTC 9.2$15.92+7% 20dTechnology - #10CERTCertara, Inc. Common Stock77
A 77 squeeze score and active buyback are fighting a deteriorating P&L and $295M in term debt, with no catalyst until August earnings.
SI 27%DTC 7.4$5.49+3% 20dHealthcare - #11GPGIGPGI, Inc.77
A 35.6% short interest and 15.8 days to cover are textbook, but 0.58% borrow costs and the Husky dilution overhang make this a low-conviction trap.
SI 36%DTC 15.8$14.48+18% 20dIndustrials - #12MBCMasterBrand, Inc.76
A 33.87% surge in short interest post-merger creates a squeeze setup, but weak Q1 fundamentals and negative analyst sentiment keep confidence at 35.
SI 28%DTC 6.7$9.61+3% 20dConsumer Cyclical - #13TNGXTango Therapeutics, Inc.75
41% of float sold short · 13.0 days to cover · +53% over 20 days
SI 41%DTC 13.0$30.14+53% 20dHealthcare - #14QDELQuidelOrtho Corporation Common75
18% of float sold short · 6.8 days to cover · +10% over 20 days
SI 18%DTC 6.8$13.52+10% 20dHealthcare - #15CAICaris Life Sciences, Inc. Comm75
95% of float sold short · 4.2 days to cover · +22% over 20 days
SI 95%DTC 4.2$18.70+22% 20dHealthcare
See the full ranked board
This is the top sliver of 15 names we rank every day. The live board carries rank history, days-to-cover fuel gauges, AI research, and a backtested signal validator.
Open the live squeeze board →